Thursday, Benitec Biopharma Inc (NASDAQ:BNTC) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study’s first subject (Subject 1) treated in the BB-301 Phase 1b/2a study in Oculopharyngeal Muscular Dystrophy (OPMD).
“To date, no clinical studies have systematically demonstrated a clinical improvement in OPMD patients across both objective and subjective measures of swallowing. We are, therefore, pleased to report positive interim clinical data from multiple radiographic measures as well as subject-reported outcome measures from the first subject treated with BB-301,” said Jerel Banks, Executive Chairman and Chief Executive Officer of Benitec.
During the OPMD Natural History Study, which represents the pre-dose observational period for each subject, Subject ...